Adage Capital Partners
BOLT icon

Adage Capital Partners’s Bolt Biotherapeutics BOLT Stock Holding History

Adage Capital Partners’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$324K – 888
2024
Q3 		$324K Hold
25,000
– – ﹤0.01% 823
2024
Q2 		$375K Hold
25,000
– – ﹤0.01% 820
2024
Q1 		$700K Hold
25,000
– – ﹤0.01% 802
2023
Q4 		$560K Hold
25,000
– – ﹤0.01% 780
2023
Q3 		$520K Hold
25,000
– – ﹤0.01% 779
2023
Q2 		$640K Hold
25,000
– – ﹤0.01% 779
2023
Q1 		$695K Buy
+25,000
New +$732K ﹤0.01% 812

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners's BOLT Position: Q4 2024 in Review

Adage Capital Partners sold out of Bolt Biotherapeutics (BOLT) in Q4 2024, closing a stake of 25,000 shares — an estimated $324K sold.

Adage Capital Partners first reported a position in BOLT in Q1 2023 and held it in 7 quarters. The position peaked at $700K in Q1 2024. 37 funds tracked by Wall St. Rank hold BOLT as of Q4 2024.

  • Adage Capital Partners reported no remaining Bolt Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 25,000 Bolt Biotherapeutics shares in Q4 2024, an estimated $324K.
  • Adage Capital Partners first reported a position in Bolt Biotherapeutics in Q1 2023 and held it in 7 quarters.
  • Adage Capital Partners's Bolt Biotherapeutics position peaked at $700K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.